X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs GLENMARK PHARMA - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS GLENMARK PHARMA J.B.CHEMICALS/
GLENMARK PHARMA
 
P/E (TTM) x 13.3 20.3 65.6% View Chart
P/BV x 2.1 3.6 57.9% View Chart
Dividend Yield % 0.2 0.3 55.4%  

Financials

 J.B.CHEMICALS   GLENMARK PHARMA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
GLENMARK PHARMA
Mar-17
J.B.CHEMICALS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs318993 32.0%   
Low Rs200729 27.4%   
Sales per share (Unadj.) Rs148.0325.5 45.5%  
Earnings per share (Unadj.) Rs19.139.3 48.6%  
Cash flow per share (Unadj.) Rs23.948.7 49.2%  
Dividends per share (Unadj.) Rs0.502.00 25.0%  
Dividend yield (eoy) %0.20.2 83.2%  
Book value per share (Unadj.) Rs128.9159.2 81.0%  
Shares outstanding (eoy) m84.82282.17 30.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.6 66.1%   
Avg P/E ratio x13.621.9 61.9%  
P/CF ratio (eoy) x10.817.7 61.1%  
Price / Book Value ratio x2.05.4 37.1%  
Dividend payout %2.65.1 51.5%   
Avg Mkt Cap Rs m21,951242,991 9.0%   
No. of employees `0002.713.0 21.1%   
Total wages/salary Rs m1,84116,408 11.2%   
Avg. sales/employee Rs Th4,590.97,083.9 64.8%   
Avg. wages/employee Rs Th673.41,265.4 53.2%   
Avg. net profit/employee Rs Th592.1855.1 69.2%   
INCOME DATA
Net Sales Rs m12,55191,857 13.7%  
Other income Rs m542374 144.9%   
Total revenues Rs m13,09392,230 14.2%   
Gross profit Rs m2,05520,367 10.1%  
Depreciation Rs m4122,644 15.6%   
Interest Rs m962,373 4.0%   
Profit before tax Rs m2,08815,724 13.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m4693,827 12.3%   
Profit after tax Rs m1,61911,088 14.6%  
Gross profit margin %16.422.2 73.8%  
Effective tax rate %22.524.3 92.3%   
Net profit margin %12.912.1 106.8%  
BALANCE SHEET DATA
Current assets Rs m7,77868,746 11.3%   
Current liabilities Rs m4,35827,027 16.1%   
Net working cap to sales %27.245.4 60.0%  
Current ratio x1.82.5 70.2%  
Inventory Days Days5585 64.3%  
Debtors Days Days8096 83.8%  
Net fixed assets Rs m5,71324,132 23.7%   
Share capital Rs m170282 60.1%   
"Free" reserves Rs m10,54744,643 23.6%   
Net worth Rs m10,93744,925 24.3%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m15,574117,639 13.2%  
Interest coverage x22.87.6 299.3%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.80.8 103.2%   
Return on assets %11.011.4 96.2%  
Return on equity %14.824.7 60.0%  
Return on capital %20.019.1 104.3%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16956,152 11.0%   
Fx outflow Rs m1,2858,084 15.9%   
Net fx Rs m4,88448,068 10.2%   
CASH FLOW
From Operations Rs m1,3976,574 21.2%  
From Investments Rs m-320-7,124 4.5%  
From Financial Activity Rs m-1,1965,432 -22.0%  
Net Cashflow Rs m-1021,992 -5.1%  

Share Holding

Indian Promoters % 55.4 48.3 114.7%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 6.9 49.1%  
FIIs % 3.9 34.4 11.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 10.5 352.4%  
Shareholders   30,437 56,727 53.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   WOCKHARDT LTD.  UNICHEM LAB  DR. REDDYS LAB  BIOCON LTD  ALEMBIC LTD  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Analysis of IPOs Launched in 2018, Governments Effort to Boost Aviation Infrastructure and Key Stocks in Action Today(Pre-Open)

The returns from initial public offers (IPOs) launched in 2018 are mixed. Comparing the gain/ (loss) since the listing date as mentioned in the last column, seven stocks are in the negative territory.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Jun 21, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS